Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $85.4 million.

  • Ascendis Pharma A's Free Cash Flow rose 19172.39% to $85.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $64.6 million, marking a year-over-year increase of 11957.04%. This contributed to the annual value of $60.9 million for FY2025, which is 11861.52% up from last year.
  • As of Q4 2025, Ascendis Pharma A's Free Cash Flow stood at $85.4 million, which was up 19172.39% from $2.5 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Free Cash Flow registered a high of $85.4 million during Q4 2025, and its lowest value of -$192.1 million during Q4 2021.
  • Over the past 5 years, Ascendis Pharma A's median Free Cash Flow value was -$99.1 million (recorded in 2021), while the average stood at -$90.0 million.
  • In the last 5 years, Ascendis Pharma A's Free Cash Flow plummeted by 13456.6% in 2021 and then soared by 19172.39% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Free Cash Flow stood at -$192.1 million in 2021, then rose by 26.76% to -$140.7 million in 2022, then soared by 67.47% to -$45.8 million in 2023, then crashed by 103.56% to -$93.2 million in 2024, then soared by 191.72% to $85.4 million in 2025.
  • Its Free Cash Flow was $85.4 million in Q4 2025, compared to $2.5 million in Q3 2025 and -$8.3 million in Q2 2025.